A Case of Advanced Gastric Cancer Showing HER2 Positivity After Chemotherapy

Overview

Journal Int Cancer Conf J

Specialty Oncology

Date 2020 Jun 26

PMID 32582513

Citations 1

Authors

Suguru Hirose

Toshikazu Moriwaki

Masamichi Yamaura

Daisuke Suganuma

Hiroki Tajima

Masashi Sato

Chiaki Enami

Takeshi Yamada

Yoshiyuki Yamamoto

Noriaki Sakamoto

Ichinosuke Hyodo

Affiliations

Soon will be listed here.

Abstract

A 63-year-old man had advanced poorly differentiated gastric adenocarcinoma with para-aortic lymph node metastases. No HER2 expression was observed in four endoscopic biopsies from the primary tumor. Tumors shrunk after S-1 with cisplatin treatment, and he underwent simple gastrectomy due to stenosis. Interestingly, HER2 diffusely overexpressed in the resected surgical specimen. His disease was stable with trastuzumab-containing therapy for 6.4 months. This case may suggest a selection of HER2-positive cells that were insensitive to the chemotherapy, and further study is needed for the change of intratumoral HER2 heterogeneity after chemotherapy.

Citing Articles

The perspectives of molecularly targeted therapies which this issue illustrates.

Matsumura N Int Cancer Conf J. 2020; 9(3):101.

PMID: 32582510 PMC: 7297898. DOI: 10.1007/s13691-020-00423-5.

References

Yang J, Luo H, Li Y, Li J, Cai Z, Su X . Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2011; 62(1):221-8. DOI: 10.1007/s12013-011-9286-1. View

Warneke V, Behrens H, Boger C, Becker T, Lordick F, Ebert M . Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol. 2012; 24(3):725-33. PMC: 3574551. DOI: 10.1093/annonc/mds528. View

Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R . Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014; 465(2):145-54. DOI: 10.1007/s00428-014-1597-3. View

Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(9):1109-1133. PMC: 10191182. DOI: 10.6004/jnccn.2019.0043. View

Lee S, De Boer W, Fermoyle S, Platten M, Kumarasinghe M . Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011; 59(5):832-40. DOI: 10.1111/j.1365-2559.2011.04017.x. View

Ross J, Fletcher J . The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998; 16(6):413-28. DOI: 10.1002/stem.160413. View

Wilke H, Muro K, Van Cutsem E, Oh S, Bodoky G, Shimada Y . Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224-35. DOI: 10.1016/S1470-2045(14)70420-6. View

Lee H, Park K, Yoo S, Nam S, Park D, Kim H . Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2012; 49(6):1448-57. DOI: 10.1016/j.ejca.2012.10.018. View

Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T . Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. Target Oncol. 2017; 12(3):341-351. DOI: 10.1007/s11523-017-0493-6. View

10.

Kang Y, Boku N, Satoh T, Ryu M, Chao Y, Kato K . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. View

11.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

12.

Kim M, Lee H, Yang H, Bang Y, Kim W . Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011; 59(5):822-31. PMC: 3267049. DOI: 10.1111/j.1365-2559.2011.04012.x. View

13.

Kolostova K, Matkowski R, Gurlich R, Grabowski K, Soter K, Lischke R . Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology. 2015; 68(4):1095-102. PMC: 4960158. DOI: 10.1007/s10616-015-9866-9. View

14.

Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M . Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2005; 15(1):65-71. View

15.

Janjigian Y, Werner D, Pauligk C, Steinmetz K, Kelsen D, Jager E . Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012; 23(10):2656-2662. DOI: 10.1093/annonc/mds104. View

16.

Wang T, Hsieh E, Henry P, Hanna W, Streutker C, Grin A . Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. Hum Pathol. 2014; 45(5):970-5. DOI: 10.1016/j.humpath.2013.12.010. View

17.

Pirrelli M, Caruso M, Di Maggio M, Armentano R, Valentini A . Are biopsy specimens predictive of HER2 status in gastric cancer patients?. Dig Dis Sci. 2012; 58(2):397-404. DOI: 10.1007/s10620-012-2357-3. View

18.

Tsai C, Chang K, Perng R, Mitsudomi T, Chen M, Kadoyama C . Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst. 1993; 85(11):897-901. DOI: 10.1093/jnci/85.11.897. View

19.

Tominaga N, Gotoda T, Hara M, Hale M, Tsuchiya T, Matsubayashi J . Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2015; 19(2):553-560. PMC: 4824804. DOI: 10.1007/s10120-015-0502-3. View

20.

Boku N . HER2-positive gastric cancer. Gastric Cancer. 2013; 17(1):1-12. PMC: 3889288. DOI: 10.1007/s10120-013-0252-z. View